JPRN-UMIN000028905已完成3 期
A multicenter, phase 3 study assessing efficacy and safety of the Sirolimus in the Treatment of intractable lymphatic anomalies (SILA study) - Sirolimus for Intractable Lymphatic Anomalies
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Past usage of mTOR inhibitors or other molecular target drugs relating mTOR pathway within 8 weeks 2) Patients who currently have an uncontrolled infection 3) Karnofsky Performance Status (PS) <= 30 (10 years of age) or Lansky play PS <= 30 (< 10 years of age) 4) Uncontrolled diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, chronic liver disease, or chronic renal disease 5) Chronic treatment (>= 4 weeks) with systemic steroids or another immunosuppressive agent at entry. Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. 6) History of allergy to sirolimus, or additive substance 7) Patients must also avoid strong inducers of CYP3A4, and may not have received these medications within 1 week of entry. 8) Known history of HIV seropositivity or known immunodeficiency 9) Hepatitis B virus carrier and/or Hepatitis C virus carrier 10) Malabsorption of sirolimus 11) Patients who have undergone surgical resection or interventional radiology procedures for target lesions within 2 weeks 12) Patients who have received therapeutic medication for a target disease within 2 weeks 13) Patients who have received chemotherapy drugs that cause bone marrow suppression, biological drug, or off-label products within 4 weeks 14) Patients who have received radiation therapy for target lesions within 24 weeks 15) Patients who have participated another clinical trial within 4 weeks 16) Patients who have dental braces or prosthesis only if it interferes with radiologic analysis of lymphatic anomaly 17) Pregnant, probably pregnant, or breast-feeding woman. Patients who do not agree birth control during clinical trial. 18) Patient who is judged inappropriate to participate in this study by the investigators
研究者
相似试验
已完成
3 期
A multicenter, phase 3 study assessing efficacy and safety of the Sirolimus (Granules and Tablets) in the Treatment of intractable vascular anomaliesKaposiform hemangioendothelioma or Tufted angioma Lymphangioma (cystic lymphatic malformation), lymphangiomatosis (generalized lymphatic anomaly) or Gorham-Stout disease Venous malformation or blue rubber bleb nevus syndrome Complex-combined vascular malformations or Klippel-Trenanay-Weber syndromeJPRN-UMIN000038973Gifu University Hospital10
招募中
1 期
lcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitislcerative ColitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2022-501788-41-00Abbvie Deutschland GmbH & Co. KG112
进行中（未招募）
1 期
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's DiseaseCTIS2023-509618-12-00AbbVie Deutschland GmbH & Co. KG137
进行中（未招募）
不适用
A clinical trial with a subcutaneous immunoglobulin (LFB-IgSC) to evaluate its efficacy, its safety and its behaviour in human blood in patients with Primary Immunodeficiency (PID) syndromesPrimary Immunofediciency (PID) syndromesMedDRA version: 16.0Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870EUCTR2013-000620-34-HUFB Biotechnologies55
进行中（未招募）
不适用
A clinical trial with a subcutaneous immunoglobulin (LFB-IgSC) to evaluate its efficacy, its safety and its behaviour in human blood in patients with Primary Immunodeficiency (PID) syndromesPrimary Immunofediciency (PID) syndromesMedDRA version: 14.1Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870EUCTR2013-000620-34-DEFB Biotechnologies55